



MPS PHARMAA LIMITED

(FORMERLY ADVIK LABORATORIES LIMITED)

Date: 03rd February, 2026

To,
The Manager (Listing)
Bombay Stock Exchange Limited,
01st Floor, P.J. Tower
Dalal Street, Mumbai-400001

Sub: Submission of Newspaper Publication w.r.t. Un-audited Financial Results for the quarter & nine months ended 31st December, 2025

Ref: BSE Scrip Code– 531686; ASE Scrip Code– 01636 (ADVIK LABO)

Dear Sir,

Pursuant to Regulation 47 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, please find enclosed herewith a copy of newspaper publication w.r.t Un-audited Financial Results for the quarter & nine months ended 31st December, 2025, published on 03rd February, 2026 in “Financial Express,” English Newspaper, & “Jansatta”, Hindi Newspaper, All India edition.

We hope that you will find the above in order. This is for your information and records please.

Thanking You.

Yours Truly,

For MPS Pharmaa Limited
(Formerly Advik Laboratories Limited)

POOJA

CHUNI

Pooja Chuni

Company Secretary

Digitally signed by
POOJA CHUNI
Date: 2026.02.03
15:33:41 +05'30'

Encl: As Above

CC.:

The Manager (Listing),
Ahmedabad Stock Exchange Limited,
01st Floor, Kamdhenu Complex,
Opp. Sahajanand College
Panjara Pole, Ambawadi, Ahmedabad – 380015

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001

Phones: 011-42424884, 43571040-45, Fax: 011-43571047

Regd. Office & Factory: 138. Roz-Ka-Meo Industrial Area, Sohna - 122103 (Distt.Mewat), Haryana

Phones: 0124-2362471 Email:info@mpspharmaa.com Website: www.mpspharmaa.com


Indian Bank
Corporate Office, Chennai

Indian Bank, a leading Public Sector Bank, has floated an RFP for Procurement of 647 nos. of CTS Scanners.

Interested parties may refer Bank's Website:

<https://www.indianbank.bank.in/tenders/> & GeM portal for details.

This is an advertisement for information purposes only and not for public defined herein shall have the meaning assigned to it in the letter of offer Limited ("NSE").



Please scan this QR code to view the Letter of Offer

Our Company was originally formed as a Partnership Firm under the name of U28995KA2021PTC145718 issued by Registrar of Companies, Central Reg was changed to "Presstonic Engineering Limited" vide a fresh Certificate U28995KA2021PLC145718 issued by Registrar of Companies - Bangalore.

Registered Office: Khata No. 161 Site # 275

Contact Person

OUR PROMOTERS: MR.

FOR PRIVATE CIRCULATION TO ELIGIBLE EQUITY

ISSUE OF UP TO 77,07,480 EQUITY SHARES OF FACE VALUE OF ₹10/- (RU SHARE) AGGREGATING UP TO ₹ 2,697.62LAKH(1) ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS AS ON THE RECORD DATE, THURS. OF THIS LETTER OF OFFER.

¹ Assuming full subscription with respect to Rights Equity Shares. Subject to finalisation of

NOTICE TO TH

ISSUE OPENS ON
FRIDAY, FEBRUARY 06, 2026

*Eligible Equity Shareholders are requested to ensure that renunciation of the Issue Closing Date.

**Our Board will have the right to extend the Issue Period as it may defer shall be permitted by any Applicant after the Issue Closing Date.

ASBA* Simple, Safe, Smart way of Application - Make use of it

Payment Schedule of Rights Equity Shares: Rs. 35/- per Rights Equity Share FACILITIES FOR APPLICATION IN THIS ISSUE:

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Circulars, all investors desiring to make an Application in this Issue are a process. Investors should carefully read the provisions applicable to an Application through ASBA. For details refer to "Terms of the Issue - Pre Issue" on page 64 of the Letter of Offer.

Please note that subject to SCSBs complying with the requirements of the periods stipulated therein, Applications may be submitted at the Design in terms of the SEBI ICDR Master circular, it is clarified that for making account using ASBA facility, each such SCSB should have a separate account registered SCSB(s). Such account shall be used solely for the purpose of a clear demarcated funds should be available in such account for such an Account

CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY with Regulation 77A of the SEBI ICDR Regulations read with the SEBI ICDR Entitlements and Allotment of Rights Equity Shares shall be made in demat Pursuant to the requirements of the SEBI ICDR Regulations and other have been credited to the demat account of the eligible equity share. INE0R1620012 on January 30, 2026.

RE holders can apply for Rights Issue or renounce the REs in full or in part the secondary market platform of the Stock Exchange (the "On Market Renunciation" transfer (the "Off Market Renunciation") within the timelines mentioned

PLEASE NOTE THAT CREDIT OF THE RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS AND THE INVESTORS FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE TOWARDS SHARES APPLIED. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED



IT- Contact Centre Operations, GITC (Global IT Centre), Navi Mumbai

Expression of Interest (EOI) for Implementation and Maintenance of Contact Centre Technology

SBI invites Expression of Interest (EOI) for exploring the market to identify Experienced and Capable players in managing Contact Centres for Implementation and Maintenance of Tech Stack.

EOI NO.: SBI/GITC/IT-Contact Centre Operations/2025/2026/53

For details/downloading EOI, please visit 'Procurement News' at Bank's website - <https://sbi.bank.in/>

Bidders are required to submit EOI Bids on <https://etender.sbi/SBI>

Last date for submission: on or before 5.00 P.M. on 25.02.2026.

Any relative addendum/corrigendum shall be posted on the Banks website only.

Place: Navi Mumbai

Date: 03.02.2026

Deputy General Manager
(IT-CC Ops)



MPS PHARMAA LIMITED

(Formerly Advik Laboratories Limited)

Regd. Off.: 138, Roza Ka Meo Indl. Area, Sohna, Distt. Mewat, Haryana - 122103

CIN : L74899HR1994PLC038300 Tele nos.: 011-42424884, 43571043-45,

Website: www.mpspharmaa.com, Email: info@mpspharmaa.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2025

(Rs. in Lacs except EPS)

| Particulars | For the quarter ended 31.12.2025 (Un-audited) | For the nine months ended 31.12.2025 (Un-audited) | For the quarter ended 31.12.2024 (Un-audited) |
|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------------------|-----------------------------------------------|
| Total Income from operations | | | 4.38 |
| Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items) | (22.95) | (68.83) | (17.79) |
| Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items) | (22.95) | (68.83) | (17.79) |
| Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items) | (22.03) | (66.06) | (17.46) |
| Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | (21.78) | (65.32) | (17.25) |
| Equity Share Capital | 1,911.14 | 1,911.14 | 1,911.14 |
| Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) | | | |
| Basic : | (0.12) | (0.35) | (0.09) |
| Diluted: | (0.12) | (0.35) | (0.09) |

Note: The above is an extract of the detailed format of Unaudited Financial Results for the Quarter & nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the aforesaid Quarterly Financial Results is available on the Stock Exchanges websites, viz., www.bseindia.com, www.aselindia.co.in and on the Company's website www.mpspharmaa.com & can also be accessed by scanning the given QR Code.

For and on behalf of the Board of Directors of
MPS Pharmaa Limited
(Formerly Advik Laboratories Limited)



Sd/-
Peeyush Kumar Aggarwal
Chairman
(DIN: 00090423)

Place: New Delhi
Date: 02th February, 2026

PUDUMJEE PAPER PRODUCTS LIMITED

CIN: L21098PN2015PLC153717

Registered Office : Thergaon, Pune - 411033. Tel.: 020-40773423

Website: www.pudumjee.com

E-mail: investors.relations@pudumjee.com

NOTICE OF POSTAL BALLOT AND REMOTE E-VOTING INFORMATION

Notice is hereby given that in compliance with Section 108, 110 and other applicable provisions if any, of the Companies Act, 2013 ("the Act"), read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014, ("the Rules"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), General Circular Nos. 14/2020 dated April 08, 2020, 17/2020 dated April-13, 2020, 20/2020 dated May 05, 2020, 22/2020 dated June 15, 2020, 33/2020 dated September 28, 2020, 39/2020 dated December 31, 2020, 10/2021 dated June 23, 2021, 20/2021 dated December 08, 2021, 3/2022 dated May 05, 2022, 11/2022 dated December 28, 2022, 09/2023 dated September 25, 2023, 09/2024 dated September 19, 2024 and 03/2025 dated September 22, 2025 and other relevant circulars issued by Ministry of Corporate Affairs (collectively referred to as MCA Circulars), Secretarial Standard

